A new study provides the first empirical evidence for tailoring BMI thresholds for diabetes screening in low- and middle-income countries.
- An enzyme called serum- and glucocorticoid-regulated kinase drives insulin resistance in the liver, thereby contributing to type 2 diabetes.
- Blocking expression of the enzyme in mice caused the liver to become more sensitive to insulin.
BOSTON – A central feature of type 2 diabetes is an inability of the body’s cells to respond to insulin, a hormone that keeps blood glucose levels normal. Critical to this balance is the liver, which both stores and manufactures glucose depending on the body’s need. New research published in Cell Reports that was led by investigators at Massachusetts General Hospital (MGH) indicates that an enzyme called serum- and glucocorticoid-regulated kinase (SGK) drives insulin resistance in the liver and therefore may represent a promising therapeutic target for type 2 diabetes.
“We decided to study the role of SGK in insulin action and metabolism because the field has assumed, since it looks very similar to another insulin-activated kinase called Akt, that SGK would do the same thing as Akt,” says senior author Alexander A. Soukas, MD, PhD, a principal investigator in MGH’s Center for Genomic Medicine and Diabetes Unit and an associate professor of medicine at Harvard Medical School. “We had the idea, based upon some early experiments, that it might actually be working in opposition to Akt, and that it might represent a way to target insulin resistance in diabetes in a very different way, promoting metabolic health and insulin sensitivity.”
Indeed, the team’s experiments revealed that when mice ate an unhealthy diet, Sgk (the mouse version of SGK) hindered the action of insulin by inhibiting the beneficial metabolic effects of a liver molecule called AMP-activated protein kinase (AMPK). Blocking Sgk activity released the brakes on AMPK, causing the liver to be more sensitive to insulin and to burn fat in the process. “In this way, targeting Sgk may be a way to target metabolic changes in type 2 diabetes in a way not previously thought possible,” says Soukas.
The findings indicate that inhibiting SGK activity in the liver might prevent the insulin resistance that is typical of type 2 diabetes. “In essence, blocking SGK in the liver restores more normal insulin action, in the process helping to block the buildup of fat in the liver and the weight gain that so frequently accompany eating a Western diet,” explains Soukas. “While we wouldn’t expect this to give people the power to eat fast food with impunity, when combined with exercise and attempts to eat more healthily, treatments like this could revolutionize the way we treat type 2 diabetes.”
Co-authors of the study include Ben Zhou, Yuyao Zhang, Lainan Li, Lianfeng Wu, Geza Fejes-Toth, and Aniko Naray-Fejes-Toth.
This work was supported by the National Institutes of Health, the Howard M. Goodman Fellowship, a Glenn Foundation Award for Research on the Biological Mechanisms of Aging, the Weissman Family Massachusetts General Hospital Research Scholar Award, and an MGH Executive Committee on Research Postdoctoral Fellowship.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."